Credit Suisse Upgrades BioMarin Pharmaceutical (BMRN) to Overweight
More News related to BMRN
- BioMarin Pharmaceutical (BMRN) Announces FDA Grants Orphan Drug Designation for 3,4-DAP
- FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
- BioMarin to Present at the NASDAQ OMX 23rd Investor Program
- BioMarin (BMRN) Responds to News of Contamination at Genzyme (GENZ) Plant; Says Aldurazyme, Naglazyme Won't Be Impacted
- Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
More News related to Upgrades
- United Community Financial (UCFC) and United Bancshares (UBOH) To Sell Findlay, OH Branch to The Union Bank Co.
- GE receives French notice that its Areva bid wasn't chosen
- Health Management Associates (HMA) Completes Acquisition of Sparks Health System
- Wright Medical (WMGI) Reports Favorable Ruling in Stryker (SYK) Patent Infringement Case
- United Rentals (URI) Awarded Purchasing Contracts in Massachusetts and Texas
Credit Suisse upgrades BioMarin Pharmaceutical (Nasdaq: BMRN) from Neutral to Overweight. Price target increased from $19 to $25.
To see more analyst ratings on BMRN Click Here.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions.
Related Categories
UpgradesStocks Mentioned
+0.05Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
